Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsBacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.
Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, ...
Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.
Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors a more dependable way ...
1.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
2.
On all CAR-T products, the FDA is calling for a new boxed warning.
3.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
4.
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
5.
Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.
1.
Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma
2.
A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%
3.
The Growing Challenge of Haematological Malignancies in Older Adults
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Thromboprophylaxis In Medical Settings- An Update
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation